C-Suite COVID-19 Challenges - Ep 3
Send us a text Critical considerations for companies developing NASH drugs Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES. Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
30 Apr 202053min
Five $imple Pieces - Ep 2
Send us a text What investors want to know about NASH development during the pandemic. Yasmeen Rahimi poses five questions NASH investors ask her about the impact of COVID-19 on NASH clinical and commercial development and our panelists provide answers in our second episode, FIVE $IMPLE PIECES: What investors want to know about NASH development during the pandemic.
23 Apr 202054min
COVID CHAOS - Ep 1
Send us a text Navigating NAFLD/NASH clinical trials through the pandemic Dr. Stephen Harrison discusses several ways the pandemic is affecting planning and execution of clinical trials and our panelists discuss implications for investors, C-suite executives and forecasters in our first episode, COVID CHAOS: Navigating NAFLD/NASH clinical trials through the pandemic. Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
15 Apr 202043min
